The current guidelines for the treatment of acute coronary syndrome and secondary prevention recommend medications such as inhibitor of platelet activation and aggregation, lipid modification drugs, β-blockers, and inhibitors of the renin-angiotensin-aldosterone system (RAAS) (Amsterdam et al., 2014; Roffi et al., 2016; Chinese Medical Association Cardiovascular Branch & Editorial Board of Chinese Journal of Cardiovascular Diseases, 2017). This evidence concerns the gene REN and acute coronary syndrome.